ClinicalTrials.gg
CompletedNCT01903252Precision-UCUpdated Aug 8, 2018Results posted

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

A Phase 3 interventional study of TP05 and Asacol 400 mg in Acute Ulcerative Colitis, sponsored by Tillotts Pharma AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by Tillotts Pharma AG (part of Zeria Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
817
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies in Colitis, Ulcerative with a site in Switzerland — 10 open to participants now, 21 under way, 12 of them phase 3. Colitis, Ulcerative · Switzerland.

Enrollment
16th of 50
817 · median 540
Started
2013
the only one that year
Phase 3
31 of 61
5 open now
Registered
8th of 61
by date

Among the 61 studies in Colitis, Ulcerative with a site in Switzerland, this one is the 16th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2013, is one of 31 in phase 3, and was the 8th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

10 of the 61 studies in Colitis, Ulcerative with a site in Switzerland are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Colitis, Ulcerative with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1).

(1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.

Read the detailed description

This is a Phase 3, randomised, double-blind, active-controlled, multi-centre, non-inferiority trial evaluating the safety and efficacy of 3.2 g of TP05/day compared to 3.2 g/day of Asacol™ with an open label extension to assess the long-term safety and tolerability of TP05 administered over a 26 week period. A total of 817 subjects with mildly to moderately active UC were evaluated. Eligible subjects were randomly assigned in a 1:1 ratio to receive 3.2 g/day of TP05 (administered once daily(OD)) or 3.2 g/day of Asacol™. The primary efficacy outcome was assessed at Week 8. All subjects who respond to TP05/Asacol™ (response or remission) continued receiving blinded study treatment for up to 12 weeks. After that, subjects could enroll in an Open Label Extension (OLE) for 26 weeks duration to receive TP05. Subjects failing to respond to study drug at the Week 8 visit could enroll in the OLE at week 8 and received 4.8 g/day of TP05.

03

Conditions studied

  • Acute Ulcerative Colitis

Browse trials for

Keywords

  • UC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Induction phase - Main criteria for inclusion include:

  1. Male or non-pregnant, non-lactating females, 18 years of age or older. Females of child bearing potential must have a negative serum pregnancy test prior to randomisation, and must use a hormonal (oral, implantable or injectable) or barrier method of throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or [defined as a minimum of one year since the last menstrual period]).
  2. Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.
  3. Active UC defined by:

    • a. Mayo score of ≥ 5
    • b. Sigmoidoscopy component score ≥ 2 confirmed by central review and
    • c. Rectal bleeding component score ≥ 1
  4. Ability of the subject to participate fully in all aspects of this clinical trial.
  5. Written must be obtained and documented.

Induction Phase - Main criteria for exclusion include:

Subjects who exhibit any of the following conditions are to be excluded from the study:

(1) Severe UC defined by the following criteria: 6 bloody stools daily with one or more of the following:

  • a. oral temperature > 37.8 degrees C or > 100.0 degrees F
  • b. pulse > 90 beats/min
  • c. \< 10 g/dL (2) Treatment with oral mesalamine at a dose of > 2.4 g/day within 4 weeks prior to randomisation.

    (3) Treatment with topical therapy (mesalamine or ) within 2 weeks prior to randomisation (4) Treatment with systemic or rectal steroids within 4 weeks prior to randomisation.

    (5) Treatment with within 6 weeks prior to randomisation. (6) Treatment with infliximab or other biologics within 3 months prior to randomisation.

    (7) Treatment with antibiotics within 7 days prior to randomisation. (8) Treatment with probiotics within 7 days prior to randomisation. (9) Treatment with anti-diarrhoeal treatment within 7 days prior to randomisation.

    (10) Treatment with nicotine patch within 7 days prior to randomisation. (11) Received any drug within 30 days prior to randomisation. (12) History of colectomy or partial colectomy. (13) History of definite dysplasia in colonic . (14) Crohn's disease. (15) Immediate or significant risk of toxic megacolon. (16) Known bleeding disorders. (17) to salicylates, aspirin, sulfasalazine or mesalazine. (18) Serum creatinine > 1.5 times the . (19) (AST), alanine aminotransferase (ALT), total or alkaline phosphatase > 2 times the upper limit of the normal range.

    (20) Serious underlying disease other than UC which in the opinion of the investigator may interfere with the subject's ability to fully participate in the study.

    (21) History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.

    (22) Stools positive for Clostridium difficile toxin. (23) Pregnant or lactating women. (24) Prior enrolment in the study.

OLE - Main criteria for inclusion include:

  1. Attendance at the Week 8 visit and completion of disease activity assessments prior to enrolment in OLE at Week 12 (responders or remitters) or Week 8 (non-responders).
  2. At least 75% compliance with study medication in the induction phase.

OLE - Main criteria for exclusion include:

(1) Withdrawal from the induction phase prior to the Week 8 visit.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
817 participants (actual)

Study arms

  • Experimental
    TP05 (Mesalazine) 1600mg

    week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)

    Drug: TP05

  • Active comparator
    Asacol 400 mg (Tillotts Pharma)

    week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)

    Drug: Asacol 400 mg

Interventions

  • DrugTP05

    3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)

    Also known as: Mesalazine 1600 mg

  • 3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)

    Also known as: Mesalazine (Tillotts Pharma AG)

06

What researchers measure

Primary outcomes

  1. Period 1: Clinical and Endoscopic Remission

    Mayo Score of \<= 2 points with no individual sub-score \> 1

    Time frame: Week 8

  2. Period 2: Clinical Response, Open-Label Extended Induction

    A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

    Time frame: Week 16

  3. Period 3: Clinical Remission

    Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

    Time frame: Week 38

Secondary outcomes

  1. Period 1: Endoscopic Remission

    Endoscopic remission was defined as a Mayo endoscopy subscore of 0

    Time frame: Week 8

  2. Period 1: Endoscopic Response

    Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.

    Time frame: Week 8

  3. Period 1: Clinical Remission

    Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

    Time frame: Week 8

  4. Period 1: Rectal Bleeding Sub-score of 0

    Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score

    Time frame: Week 8

  5. Period 1: Clinical and Endoscopic Response

    Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.

    Time frame: Week 8

  6. Period 1: Clinical Remission

    Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

    Time frame: Week 12

  7. Period 1: Clinical Response

    A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

    Time frame: Week 12

  8. Period 1: Rectal Bleeding Score of 0

    Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score

    Time frame: Week 12

  9. Period 1: Clinical Remission at Both Week 8 and 12

    Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

    Time frame: Week 8 and week 12

  10. Period 1: Clinical Response at Both Week 8 and Week 12

    A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

    Time frame: Week 8 and Week 12

  11. Period 1: Change in Mayo Score From Baseline

    Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups. The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.

    Time frame: Baseline and Week 8

  12. Period 1: Change in Partial Mayo Score From Baseline

    Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.

    Time frame: Baseline and Week 8

  13. Period 1: Change in Stool Frequency Score

    Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.

    Time frame: Baseline and Week 8

  14. Period 1: Change in Rectal Bleeding Score From Baseline

    Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.

    Time frame: Baseline and Week 8

  15. Period 1: Change in Physician Global Assessment Score From Baseline

    Between-Group Difference of Physician Global Assessment Score, Change from Baseline. The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.

    Time frame: Baseline and Week 8

  16. Period 1: Change in Endoscopic Score From Baseline

    Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.

    Time frame: Baseline and Week 8

  17. Period 2: Clinical Remission

    Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

    Time frame: Week 16

  18. Period 2: Rectal Bleeding Sub-score of 0

    Percentage of patients achieving the endpoint rectal bleeding sub-score of 0

    Time frame: Week 16

  19. Period 2: Stool Frequency 0

    Percentage of patients achieving the endpoint stool frequency sub-score of 0

    Time frame: Week 16

  20. Period 2: Urgency

    Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.

    Time frame: Week 16

  21. Period 2: UC-Related Complications

    Percentage of Patients Experiencing Complications related to UC

    Time frame: Week 16

  22. Period 3: Clinical Response

    A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

    Time frame: Week 38

  23. Period 3: Clinical and Endoscopic Remission

    Mayo Score of \<= 2 points with no individual sub-score \> 1

    Time frame: Week 38

  24. Period 3: Clinical and Endoscopic Response

    Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and \> 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.

    Time frame: Week 38

  25. Period 3: Endoscopic Remission

    Percentage of each dose group achieving an endoscopy sub score of 0

    Time frame: Week 38

  26. Period 3: Endoscopic Response

    Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.

    Time frame: Week 38

  27. Period 3: Rectal Bleeding Sub Score of 0

    Percentage of each dose group achieving the endpoint rectal bleeding subscore 0

    Time frame: Week 38

  28. Period 3: Stool Frequency Sub-score 0

    Patients achieving a Stool Frequency sub-score of 0

    Time frame: Week 38

  29. Period 3: No Urgency

    No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.

    Time frame: Week 38

  30. Period 3: UC-Related Complications

    Percentage of Patients with Complications related to UC

    Time frame: Week 38

07

Results

Posted Aug 8, 2018

Participant flow

Double-Blind Induction
Participant flow — Double-Blind Induction
MilestoneTP05 (Mesalazine) 1600 mgAsacol (Mesalazine 400 mg)Extended Induction1.6g TP05 (1600 mg) /Day Maintenance Open-Label3.2g TP05 (1600 mg) /Day Maintenance Open-Label4.8g TP05 (1600 mg) /Day Maintenance Open-Label
Started4094080000
Completed3703670000
Not completed39410000
Withdrew: Adverse event20180000
Withdrew: Withdrawal by subject10130000
Withdrew: Physician decision230000
Withdrew: Non-compliance,770000
Extended Induction, Open-Label
Participant flow — Extended Induction, Open-Label
MilestoneTP05 (Mesalazine) 1600 mgAsacol (Mesalazine 400 mg)Extended Induction1.6g TP05 (1600 mg) /Day Maintenance Open-Label3.2g TP05 (1600 mg) /Day Maintenance Open-Label4.8g TP05 (1600 mg) /Day Maintenance Open-Label
Started00243000
Completed00220000
Not completed0023000
Withdrew: Adverse event0017000
Withdrew: Withdrawal by subject005000
Withdrew: Physician decision001000
Maintenance, Open-Label
Participant flow — Maintenance, Open-Label
MilestoneTP05 (Mesalazine) 1600 mgAsacol (Mesalazine 400 mg)Extended Induction1.6g TP05 (1600 mg) /Day Maintenance Open-Label3.2g TP05 (1600 mg) /Day Maintenance Open-Label4.8g TP05 (1600 mg) /Day Maintenance Open-Label
Started000202274199
Completed000196253181
Not completed00062118
Withdrew: Adverse event0003914
Withdrew: Withdrawal by subject000162
Withdrew: Other000262

Outcome measures

PrimaryPeriod 1: Clinical and Endoscopic Remission

Mayo Score of \<= 2 points with no individual sub-score \> 1

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Clinical and Endoscopic Remission
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical and Endoscopic Remission8795
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.005 · Risk difference (rd): -2.2 · 95% CI -8.1 to 3.8
PrimaryPeriod 2: Clinical Response, Open-Label Extended Induction

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: Clinical Response, Open-Label Extended Induction
ParticipantsExtended Induction
Period 2: Clinical Response, Open-Label Extended Induction183
Statistical analysis
  • Extended Induction · Percentag: 75.3 · 95% CI 69.4 to 80.6
PrimaryPeriod 3: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

Time frame:
Week 38
Reported as:
Number · percentage of participant
Period 3: Clinical Remission
percentage of participant1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Clinical Remission70.333.930.7
SecondaryPeriod 1: Endoscopic Remission

Endoscopic remission was defined as a Mayo endoscopy subscore of 0

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Endoscopic Remission
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Endoscopic Remission3644
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = <0.001 · Risk difference (rd): -2.1 · 95% CI -6.5 to 2.2
SecondaryPeriod 1: Endoscopic Response

Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Endoscopic Response
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Endoscopic Response185196
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.026 · Risk difference (rd): -3.1 · 95% CI -10.1 to 3.9
SecondaryPeriod 1: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Clinical Remission
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical Remission92110
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.048 · Risk difference (rd): -4.8 · 95% CI -10.9 to 1.4
SecondaryPeriod 1: Rectal Bleeding Sub-score of 0

Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Rectal Bleeding Sub-score of 0
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Rectal Bleeding Sub-score of 0212226
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiortiy · p = 0.042 · Risk difference (rd): -3.9 · 95% CI -10.8 to 3.1
SecondaryPeriod 1: Clinical and Endoscopic Response

Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Period 1: Clinical and Endoscopic Response
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Clinical and Endoscopic Response221236
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · Non-inferiority · p = 0.048 · Risk difference (rd): -4.2 · 95% CI -11.0 to 2.7
SecondaryPeriod 1: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Period 1: Clinical Remission
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical Remission93113
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.068 · Risk difference (rd): -5.3 · 95% CI -11.5 to 0.9
SecondaryPeriod 1: Clinical Response

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Period 1: Clinical Response
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical Response223233
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiortiy · p = 0.021 · Risk difference (rd): -2.9 · 95% CI -9.8 to 4.0
SecondaryPeriod 1: Rectal Bleeding Score of 0

Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score

Time frame:
Week 12
Reported as:
Count of participants · Participants
Period 1: Rectal Bleeding Score of 0
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Rectal Bleeding Score of 0193205
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiortiy · p = 0.031 · Risk difference (rd): -3.4 · 95% CI -10.3 to 3.7
SecondaryPeriod 1: Clinical Remission at Both Week 8 and 12

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

Time frame:
Week 8 and week 12
Reported as:
Count of participants · Participants
Period 1: Clinical Remission at Both Week 8 and 12
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical Remission at Both Week 8 and 126680
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.013 · Risk difference (rd): -3.7 · 95% CI -9.2 to 1.8
SecondaryPeriod 1: Clinical Response at Both Week 8 and Week 12

A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

Time frame:
Week 8 and Week 12
Reported as:
Count of participants · Participants
Period 1: Clinical Response at Both Week 8 and Week 12
ParticipantsTP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)
Period 1: Clinical Response at Both Week 8 and Week 12216230
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG) · Non-inferiority · p = 0.042 · Risk difference (rd): -3.9 · 95% CI -10.8 to 3.0
SecondaryPeriod 1: Change in Mayo Score From Baseline

Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups. The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Mayo Score From Baseline
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Mayo Score From Baseline3.1 ± 2.73.2 ± 2.6
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.557 · Mean difference (net): -0.1 · 95% CI -0.5 to 0.3
SecondaryPeriod 1: Change in Partial Mayo Score From Baseline

Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Partial Mayo Score From Baseline
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Partial Mayo Score From Baseline2.5 ± 2.22.5 ± 2.2
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.987 · Mean difference (net): 0.00 · 95% CI -0.3 to 0.3
SecondaryPeriod 1: Change in Stool Frequency Score

Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Stool Frequency Score
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Stool Frequency Score0.9 ± 1.10.9 ± 1.1
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.455 · Mean difference (net): 0.1 · 95% CI -0.1 to 0.2The result of the mean difference is not corresponding to the values in the table due to rounding as specified in the Statistical Analysis Plan (SAP).
SecondaryPeriod 1: Change in Rectal Bleeding Score From Baseline

Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Rectal Bleeding Score From Baseline
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Rectal Bleeding Score From Baseline0.9 ± 0.81.0 ± 0.8
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.937 · Mean difference (net): -0.00 · 95% CI -0.1 to 0.1The apparent difference between the values in the table and the mean difference is due to rounding as defined in the SAP.
SecondaryPeriod 1: Change in Physician Global Assessment Score From Baseline

Between-Group Difference of Physician Global Assessment Score, Change from Baseline. The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Physician Global Assessment Score From Baseline
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Physician Global Assessment Score From Baseline0.6 ± 0.80.7 ± 0.8
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.357 · Mean difference (net): -0.1 · 95% CI -0.2 to 0.1
SecondaryPeriod 1: Change in Endoscopic Score From Baseline

Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Period 1: Change in Endoscopic Score From Baseline
units on a scaleTP05 (Mesalazine)Asacol (Mesalazine)
Period 1: Change in Endoscopic Score From Baseline0.5 ± 0.90.6 ± 0.8
Statistical analysis
  • TP05 (Mesalazine) vs Asacol (Mesalazine) · t-test, 2 sided · p = 0.099 · Mean difference (net): -0.1 · 95% CI -0.2 to 0.0
SecondaryPeriod 2: Clinical Remission

Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: Clinical Remission
ParticipantsExtended Induction
Period 2: Clinical Remission53
Statistical analysis
  • Extended Induction · Percentage: 21.8 · 95% CI 16.8 to 27.5
SecondaryPeriod 2: Rectal Bleeding Sub-score of 0

Percentage of patients achieving the endpoint rectal bleeding sub-score of 0

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: Rectal Bleeding Sub-score of 0
ParticipantsExtended Induction
Period 2: Rectal Bleeding Sub-score of 0146
Statistical analysis
  • Extended Induction · Percentage: 60.1 · 95% CI 53.6 to 66.3
SecondaryPeriod 2: Stool Frequency 0

Percentage of patients achieving the endpoint stool frequency sub-score of 0

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: Stool Frequency 0
ParticipantsExtended Induction
Period 2: Stool Frequency 064
Statistical analysis
  • Extended Induction · Percentage: 26.3 · 95% CI 20.9 to 32.3
SecondaryPeriod 2: Urgency

Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: Urgency
ParticipantsExtended Induction
Period 2: Urgency109
Statistical analysis
  • Extended Induction · Percentage: 44.9 · 95% CI 38.5 to 51.3
SecondaryPeriod 2: UC-Related Complications

Percentage of Patients Experiencing Complications related to UC

Time frame:
Week 16
Reported as:
Count of participants · Participants
Period 2: UC-Related Complications
ParticipantsExtended Induction
Period 2: UC-Related Complications0.0
Statistical analysis
  • Extended Induction · Percentage: 0.00 · 95% CI 0.0 to 1.5
SecondaryPeriod 3: Clinical Response

A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Clinical Response
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Clinical Response94.183.978.4
SecondaryPeriod 3: Clinical and Endoscopic Remission

Mayo Score of \<= 2 points with no individual sub-score \> 1

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Clinical and Endoscopic Remission
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Clinical and Endoscopic Remission65.839.429.6
SecondaryPeriod 3: Clinical and Endoscopic Response

Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and \> 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Clinical and Endoscopic Response
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Clinical and Endoscopic Response89.678.169.3
SecondaryPeriod 3: Endoscopic Remission

Percentage of each dose group achieving an endoscopy sub score of 0

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Endoscopic Remission
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Endoscopic Remission37.632.413.6
SecondaryPeriod 3: Endoscopic Response

Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Endoscopic Response
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Endoscopic Response73.858.853.3
SecondaryPeriod 3: Rectal Bleeding Sub Score of 0

Percentage of each dose group achieving the endpoint rectal bleeding subscore 0

Time frame:
Week 38
Reported as:
Number · percentage of participants
Period 3: Rectal Bleeding Sub Score of 0
percentage of participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Rectal Bleeding Sub Score of 088.176.374.9
SecondaryPeriod 3: Stool Frequency Sub-score 0

Patients achieving a Stool Frequency sub-score of 0

Time frame:
Week 38
Reported as:
Count of participants · Participants
Period 3: Stool Frequency Sub-score 0
Participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: Stool Frequency Sub-score 014810166
SecondaryPeriod 3: No Urgency

No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.

Time frame:
Week 38
Reported as:
Count of participants · Participants
Period 3: No Urgency
Participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: No Urgency161173109
SecondaryPeriod 3: UC-Related Complications

Percentage of Patients with Complications related to UC

Time frame:
Week 38
Reported as:
Count of participants · Participants
Period 3: UC-Related Complications
Participants1.6g/Day Maintenance Open-Label3.2/Day Maintenance Open-Label4.8g/Day Maintenance Open-Label
Period 3: UC-Related Complications321

Adverse events

Collected over 2 years, 11 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TP05/TP05—24/409 (5.9%)58/409 (14.2%)
Asacol/TP05—18/408 (4.4%)75/408 (18.4%)
TP05 Extended Induction—3/243 (1.2%)0/243 (0%)
TP05—9/409 (2.2%)26/409 (6.4%)
Asacol—7/408 (1.7%)22/408 (5.4%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventTP05/TP05Asacol/TP05TP05 Extended InductionTP05Asacol
Deterioration ulcerative colitiesGastrointestinal disorders9/4096/4080/2434/4094/408
AnaemiaBlood and lymphatic system disorders2/4092/4080/2431/4091/408
DepressionPsychiatric disorders0/4092/4080/2430/4090/408
Hypertensive heart diseaseCardiac disorders1/4090/4081/2430/4090/408
Artrial fibrilationCardiac disorders1/4090/4081/2430/4090/408
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/4091/4081/2430/4090/408
PneumoniaInfections and infestations1/4091/4080/2431/4091/408
Cerebral infarctionNervous system disorders0/4091/4080/2430/4090/408
Cerebral haematomaNervous system disorders0/4091/4080/2430/4090/408
Herniated discMusculoskeletal and connective tissue disorders0/4091/4080/2430/4090/408
Most frequent other events
Most frequent other events
EventTP05/TP05Asacol/TP05TP05 Extended InductionTP05Asacol
Worsening of UCGastrointestinal disorders58/40975/4080/24326/40922/408

Baseline characteristics

Safety Population (SAF)/Intent to Treat (ITT)

Age, Continuous
Age, Continuous(years)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
Mean43.97 ± 14.5443.3 ± 14.1143.5 ± 14.32
Sex: Female, Male
Sex: Female, Male(Participants)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
Female171178349
Male238230468
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
White378386764
Black112
Asian or Pacific Islander7310
Mixed/Other011
Not Available231740
Region of Enrollment
Region of Enrollment(participants)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
Belarus474996
Belgium9817
Bulgaria151530
Canada151732
Czech Republic201838
Denmark201636
Finland213
Hungary171128
France231639
Ireland101
Latvia222244
Lithuania262854
Norway459
Poland444892
Romania213
Russian Federation5150101
Serbia181836
Slovakia235
Spain022
Sweden123
Ukraine5971130
United Kingdom11718
Mayo Score
Mayo Score(units on a scale)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
Mean7.7 ± 1.37.6 ± 1.37.7 ± 1.3
Partial Mayo Clinic Score
Partial Mayo Clinic Score(units on a scale)TP05 (Mesalazine)Asacol (Mesalazine, Tillotts Pharma AG)Total
Mean5.5 ± 1.15.3 ± 1.15.4 ± 1.1
08

Study locations

1 site
  • Tillotts Pharma AG
    Rheinfelden, Baslerstrasse 15 4310, Switzerland
09

References and documents

Publications

  • Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Feb;20(2):447-454.e1. doi: 10.1016/j.cgh.2020.11.040. Epub 2020 Dec 3. PubMed 33279779 ↗
  • Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1760-1768.e1. doi: 10.1016/j.cgh.2019.09.021. Epub 2019 Sep 20. PubMed 31546056 ↗
  • D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1. PubMed 28568974 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in May 2016, 34 months.

Results were first posted in Aug 2018, 2 years 3 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 34 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2013
First posted
Jul 19, 2013
StartActual
Jul 2013
Primary completionActual
May 2016
CompletionActual
Nov 2016
Results first posted
Aug 8, 2018
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01903252
Lead sponsor
Tillotts Pharma AG
Responsible party
Sponsor
First posted
Jul 19, 2013
Start date
Jul 2013
Primary completion
May 2016
Completion
Nov 2016
Results posted
Aug 8, 2018
Last update
Aug 8, 2018

Study contacts

Geert R D'Haens, MD, PhD
principal investigator · Alimentiv Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion